Nanobac and American Health Associates Clinical Laboratories (AHA) have reached an agreement for AHA to serve as the exclusive U.S. provider of Nanobac proprietary blood tests that can detect blood levels of Calcifying Nanoparticles (CNPs), which are found in coronary artery calcification, kidney stones, and other stone forming diseases. CNPs have been found in preliminary studies to be markers of arterial calcification, which in turn is a reliable marker of heart disease risk.

AHA is a well-established certified laboratory headquartered in Miramar, Florida, and accepts blood samples from across the U.S. The tests can detect CNP antigens and antibodies. Analysis will be performed at AHA's main laboratory in Miramar. Nanobac's laboratory in Finland will continue to service the world market after having performed thousands of such tests worldwide since the year 2000.

If you would like to know more about the NB2 test for detecting Calcifying Nanoparticles (CNPs) please complete this form.